novartis ag swiss multinational pharmaceutical corporation based basel switzerland consistently ranked global top five novartis one largest pharmaceutical companies world fourth largest revenue novartis manufactures drugs clozapine clozaril diclofenac voltaren sold glaxosmithkline deal carbamazepine tegretol valsartan diovan imatinib mesylate gleevecglivec cyclosporine neoralsandimmune letrozole femara methylphenidate ritalin production ceased terbinafine lamisil deferasirox exjade others novartis formed merger cibageigy considered largest corporate merger history pharmaceutical agrochemical divisions companies formed novartis independent entity name novartis based latin terms novae artes new merger cibageigy sandoz businesses sold like ciba specialty chemicals spun independent companies sandoz brand disappeared three years revived novartis consolidated generic drugs businesses single subsidiary named sandoz novartis divested agrochemical genetically modified crops business spinout syngenta partnership astrazeneca also divested agrochemical business new company also acquired series acquisitions order strengthen core novartis full member european federation pharmaceutical industries associations international federation pharmaceutical manufacturers associations pharmaceutical research manufacturers america novartis third valuable pharmaceutical company europe novo nordisk roche shareholders novartis country origin december novartis ag publicly traded swiss holding company operates novartis group owns directly indirectly companies worldwide operate subsidiaries novartis novartiss businesses divided two operating divisions innovative medicines sandoz eyecare division alcon spun independent company april august novartis announced plans spin sandoz part restructuring spinoff completed october innovative medicines business made two commercial units innovative medicines international innovative medicines two business units combine pharmaceutical oncology divisions commercially focus global us market novartis operates directly subsidiaries fall one divisions novartis categorizes fulfilling one following functions holdingfinance sales production novartis ag also held percent shares roche however exercise control novartis also two significant license agreements genentech roche one agreement novartis established center hyderabad india order offshore several rd clinical development medical writing administrative center supports drug majors operations pharmaceuticals novartis eye care alcon generic drugs segments novartis worlds first largest life sciences agribusiness also secondlargest pharmaceutical company market cap novartis ranked second access medicine ranks companies readily make products available worlds fiscal year novartis reported earnings billion annual revenue us billion decrease percent previous fiscal cycle novartis shares traded per share market capitalization valued january novartis created march merger cibageigy sandoz laboratories swiss companies cibageigy formed merger j r geigy ltd founded basel ciba founded basel ciba began alexander clavel took production fuchsine factory silkdyeing works basel sold dye factory company bindschedler busch bindschedler busch transformed jointstock company named gesellschaft für chemische industrie basel company chemical industry basel acronym ciba adopted companys name foundation geigy established johann rudolf geigymerian johann mullerpack acquired site basel built dyewood mill dye extraction plant two years later began production synthetic formed public limited company geigy name company changed j r geigy ltd ciba geigy merged form ltd ˌsiːbə state federal health environmental agencies identified increased incidence childhood cancers toms river new jersey period multiple investigations state federal environmental health agencies indicated likely source increased cancer risk contamination toms river chemical plant operated cibageigy operation since reich farmunion area designated united states environmental protection agency superfund site underground plume toxic chemicals identified following year discharge pipe shut sinkhole corner bay avenue vaughn avenue revealed leaking plant ceased operation followup study period indicated cancer cases expected rates significantly fallen difference statistically insignificant compared normal statewide cancer rates since toms river water system subject stringent water testing new jersey considered safe consumption dan fagins toms river story science salvation pulitzer prize winning book examined issue industrial pollution site detail sandoz generic drugs division novartis merger cibageigy form novartis sandoz pharmaceuticals sandoz ag pharmaceutical company headquartered basel switzerland cibageigy best known developing drugs sandimmune organ transplantation antipsychotic clozaril mellaril tablets serentil tablets treating psychiatric disorders cafergot tablets torecan suppositories treating migraine headaches chemiefirma kern und sandoz kern sandoz chemistry firm founded alfred kern edouard sandoz first dyes manufactured alizarinblue auramine kerns death partnership became corporation chemische fabrik vormals sandoz company began producing feverreducing drug antipyrin year company began producing sugar substitute saccharin pharmaceutical research began arthur stoll founder sandozs pharmaceutical department arthur stoll isolated ergotamine ergot substance eventually used treat migraine headaches introduced trade name gynergen world wars gynergen calciumsandoz brought market sandoz also produced chemicals textiles paper leather beginning company began producing agricultural chemicals psychedelic effects lysergic acid diethylamide lsd discovered sandoz laboratories arthur stoll albert sandoz began clinical trials marketed substance name delysid psychiatric drug thought useful treating wide variety mental ailments ranging alcoholism sexual deviancy sandoz suggested marketing literature psychiatrists take lsd gain better subjective understanding schizophrenic experience many exactly scientific researchers sandoz product received mass publicity early time magazine research lsd peaked early cia purchased quantities lsd sandoz use illegal human experimentation program known sandoz withdrew drug market drug became cultural novelty psychologist timothy leary harvard university began promote use recreational spiritual experiences among general public sandoz opened first foreign offices sandoz merged wander ag known ovomaltine isostar sandoz acquired companies delmark wasabröd swedish manufacturer crisp bread gerber products company baby food company november fire broke production plant storage room led sandoz chemical spill large amount pesticide released upper rhine river exposure killed many fish aquatic life sandoz spun specialty chemicals business form clariant clariant merged specialty chemicals business spun hoechst ag cibageigy merged sandoz pharmaceutical agrochemical divisions staying together form novartis cibageigy sandoz businesses spun independent notably ciba specialty sandozs master builders technologies producer chemicals construction industry sold skw trostberg ag subsidiary german energy company viag north american corn herbicide business became part german chemical maker company entered biotechnology licensing agreement university california berkeley department plant microbial critics agreement expressed concern prospects agreement would diminish academic objectivity lead commercialization genetically modified agreement expired novartis astrazeneca combined agrobusiness divisions create new company novartis organized generics businesses one division merged subsidiaries one company reusing predecessor brand name novartis expanded subsidiary sandoz significantly billion acquisition hexal one germanys leading generic drug companies eon labs fastgrowing united states generic pharmaceutical novartis acquired californiabased chiron corporation chiron divided three units chiron vaccines chiron blood testing chiron biopharmaceuticals biopharmaceutical unit integrated novartis pharmaceuticals vaccines blood testing units made new novartis vaccines diagnostics also sandoz became first company biosimilar drug approved europe recombinant human growth hormone novartis sold gerber products company nestlé part continuing effort shed old sandoz cibageigy businesses focus novartis reached agreement acquire percent stake chinese vaccines company zhejiang tianyuan biopharmaceutical co ltd part strategic initiative build vaccines industry leader country expand groups limited presence fastgrowing market segment proposed acquisition require government regulatory approvals novartis offered pay billion fully acquire alcon worlds largest eyecare company including majority stake held nestlé novartis bought percent alcon novartis created new division called alcon placed ciba vision subsidiary novartis ophthalmics became secondlargest division total cost alcon amounted billion novartis acquired medical laboratory diagnostics company genoptix serve strong foundation novartis individualized treatment company cut positions united states primarily sales response anticipated revenue downturns hypertension drug diovan losing patent protection realization anticipated successor diovan rasilez failing clinical personnel reductions follow cut positions switzerland united states cut positions united states reduction thousands several site closures previous also novartis became biggest manufacturer generic skin care medicine agreeing buy fougera pharmaceuticals billion indian supreme court issued decision rejecting novartis patent application india final form gleevec novartiss cancer drug case caused great novartis sued us government time allegedly bribing doctors decade patients steered towards companys january novartis announced plans cut jobs pharmaceuticals february novartis announced acquired costim may novartis purchased rights market ophthotechs fovista antipdgf aptamer also investigated use combination antivegf treatments outside us novartis acquired exclusive rights market eye drug outside states retaining us marketing rights company agreed pay ophthotech million upfront million milestone payments relating phase iii ophthotech also eligible receive million dependent upon future marketing approval milestones outside america million relating sales september ophthotech received first million phase iii trial milestone payment april novartis announced would acquire glaxosmithklines cancer drug business billion well selling vaccines business glaxosmithkline august genetic engineering biotechnology news reported novartis acquired percent stake gamida cell million option purchase whole company approximately october novartis announced intention sell influenza vaccine business inclusive development pipeline subject regulatory approval csl march company announced biopharma completed acquisition two phase iii cancerdrug candidates mek inhibitor binimetinib mek braf inhibitor encorafenib addition company sold rnai portfolio arrowhead research million million june company announced would acquire spinifex pharmaceuticals august company acquired remaining rights monoclonal antibody ofatumumab glaxosmithkline october company acquired admune therapeutics undisclosed sum well licensing adenosine receptor antagonist phase clinical trials nonsmall cell lung cancer november company announced would acquire selexys pharmaceuticals december company acquired encore vision gaining companys principle compound firstinclass topical therapy december novartis acquired ziarco group limited bolstering presence eczema late october reuters announced novartis would acquire advanced accelerator applications billion paying per ordinary share per american depositary share representing percent march glaxosmithkline announced reached agreement novartis acquire novartis percent stake consumer healthcare joint venture billion april year business utilised proceeds aforementioned glaxosmithkline deal acquire avexis per share billion total gaining lead compound used treat spinal muscular august novartis signed deal laeknaa shanghaibased pharmaceutical company two clinicalstage cancer novartis gave laekna exclusive international rights drugs oral panakt kinase inhibitors namely afuresertib uprosertib midoctober company announced would acquire endocyte inc billion per share merging newly created endocyte bolster novartis offering radiopharmaceuticals business endocytes first class candidate targeted metastatic castrationresistant prostate late december company announced would acquire francebased contract manufacturer cellforcure lfb boosting capacity produce cell gene april novartis announced completed spinoff alcon separate commercial entity alcon listed six exchange switzerland nyse exchange novartis announced late fiveyear artificial intelligence alliance microsoft companies aim create applications microsofts ai capabilities turn improving others drug development processes microsoft seeks test ai products already working reallife situations deal pursue solutions organizing using data generated novartis laboratory experiments clinical trials manufacturing plants also look improving manufacturing chimeric antigen receptor cell car cells finally deal also apply ai generative chemistry enhance drug november sandoz announced would acquire japanese business aspen global inc million around million boosting businesss presence late november business announced would acquire medicines company billion per share order acquire amongst assets cholesterol lowering therapy april company announced would acquire september novartis imposed fine million french competition authority accusations abusive practices preserve sales lucentis cheaper also september biontech leased large production facility novartis follow advance demands coronavirus vaccine europe sell october novartis announced would acquire vedere bio million boosting businesses cell gene therapy october part joint venture develop therapeutic drugs combat novartis bought shares outstanding swiss darpin research company molecular partners ag chf per december novartis announced would acquire cadent therapeutics million gaining full rights nmdar positive allosteric modulator nmdar negative allosteric modulator clinicalstage sk channel positive allosteric september company announced would acquire genetherapy business arctos medical broadening optogenetics december novartis announced would purchase gyroscope therapeutics health care investment company syncona ltd february new york citybased biotechnology company cambrian biopharma announced licensed rights mtor inhibitor programs part deal cambrian setting subsidiary called tornado august company announced plan spin sandoz generic drugs unit form publicly traded business part unit generated billion spinoff would create biggest generic drugs company europe june novartis announced would acquire chinook therapeutics drug pipeline july novartis acquired dtx pharma developer technology delivering rnabased therapies upfront million additional million subject reaching certain also june novartis announced would would sell xiidra bausch lomb billion receive additional million linked future sales xiidra well two pipeline september novartis announced spinoff approved shareholders would completed next month resulting novartis shareholders receiving one sandoz share every five novartis sandoz listed six swiss exchange market capitalization billion october novartis completed spinoff sandoz standalone november legend biotech novartis signed outlicense deal develop manufacture legend chimeric antigen receptor cart therapies go deltalike including large cell million upfront legend biotech eligible receive billion clinical regulatory commercial milestone payments tiered royalties companys global research operations called novartis institutes biomedical research nibr global headquarters cambridge massachusetts united two research institutes reside within nibr focus diseases developing world novartis institute tropical diseases works tuberculosis dengue malaria novartis vaccines institute global health works salmonella typhi typhoid fever novartis also involved publicly funded collaborative research projects industrial academic partners one example area nonclinical safety assessment innomed predtox company expanding activities joint research projects within framework innovative medicines initiative efpia european novartis working science order allow video based telemedicine visits instead physical traveling clinics patients planning ten clinical trials three years using mobile technology help free patients burdensome hospital january united states department health human services awarded novartis million contract construction first us plant produce cellbased influenza vaccine located holly springs north carolina stated goal program capability producing doses pandemic vaccine within six months declaring flu april novartis divested consumer health section billion worth assets new joint venture glaxosmithkline named gsk consumer healthcare novartis hold march gsk announced reached agreement novartis acquire novartis stake consumer healthcare joint venture billion novartis fought sevenyear controversial battle patent gleevec india took case way indian supreme court patent application finally rejected patent application center case filed novartis india india agreed enter world trade organization abide worldwide intellectual property standards trips agreement part agreement india made changes patent law biggest prior changes patents products allowed afterwards albeit restrictions changes came effect novartis patent application waited mailbox others procedures india instituted manage transition india also passed certain amendments patent law laws came effect played key role rejection patent patent claimed final form gleevec beta crystalline form imatinib india allowed patents products novartis patented imatinib salts vaguely specified many countries could patent key differences two patent applications patent application specified counterion gleevec specific salt imatinib mesylate patent application claim specific salts mention mesylate patent application specified solid form gleevec way individual molecules packed together solid drug manufactured separate processes drug formulated pills capsules patent application solid form imatinib mesylate gleevec beta provided trips agreement novartis applied exclusive marketing rights emr gleevec indian patent office emr granted november novartis made use emr obtain orders generic manufacturers already launched gleevec novartis set price gleevec per patient per month generic companies selling versions per patient per novartis also initiated program assist patients could afford version drug concurrent product examination novartis patent application began came immediate attack oppositions initiated generic companies already selling gleevec india advocacy groups application rejected patent office appeal board key basis rejection part indian patent law created amendment describing patentability new uses known drugs modifications known drugs section paragraph specified inventions patentable differ significantly properties regard one point novartis went court try invalidate paragraph argued provision unconstitutionally vague violated trips novartis lost case novartis appeal rejection patent office indias supreme court took case supreme court case hinged interpretation paragraph supreme court decided substance novartis sought patent indeed modification known drug raw form imatinib publicly disclosed patent application scientific articles novartis present evidence difference therapeutic efficacy final form gleevec raw form imatinib therefore patent application properly rejected patent office lower although court ruled took care note subject application filed time transition indian patent decision generated widespread global news coverage reignited debates balancing public good monopolistic pricing innovation affordability novartis patent issued could prevented generics companies india selling generic gleevec could obliged pay reasonable royalty grandfather clause included indias patent reaction decision ranjit shahani vicechairman managing director novartis india ltd quoted saying ruling setback patients hinder medical progress diseases without effective treatment also said companies like novartis would invest less money research india result novartis also emphasised continues committed good access drugs according novartis patients glivec free charge provided billion worth glivec indian patients support program since may jury united states district court southern district new york awarded compensatory damages novartis finding company committed sexual discrimination twelve female sales representatives entrylevel managers since matters pay promotion treatment learning employees pregnant two months later company settled remaining plaintiffs million plus attorney september us food drug administration fda sent notice novartis pharmaceuticals regarding advertising focalin xr adhd drug company overstated efficacy marketing public medical federal prosecutors opened investigation novartis marketing several drugs trileptal antiseizure drug three drugs heart conditions diovan companys topselling product exforge tekturna sandostatin drug treat growth hormone disorder zelnorm drug irritable bowel september novartis agreed pay million criminal civil claims enter corporate integrity agreement us office inspector according new york times federal prosecutors accused novartis paying illegal kickbacks health care professionals speaker programs advisory boards entertainment travel meals aside pleading guilty one misdemeanor charge mislabeling agreement novartis announced february company denied new york times article frank lichtenberg columbia professor receives pharmaceutical financing research innovation industry said offlabel prescribing encouraged american medical association paid insurers offlabel marketing clearly illegal surprising would settle dont legal leg stand april federal prosecutors filed two lawsuits novartis false claims act offlabel marketing kickbacks suits prosecutors seeking treble first suit accused novartis inducing pharmacies switch thousands kidney transplant patients immunosuppressant drug myfortic exchange kickbacks disguised rebates second justice department joined qui tam whistleblower lawsuit brought former sales rep offlabel marketing three drugs lotrel valturna hypertension drugs diabetes drug twentyseven states district columbia chicago new york also outside us novartis markets drug ranibizumab trade name lucentis monoclonal antibody fragment derived parent mouse antibody bevacizumab avastin avastin lucentis created genentech owned roche roche markets avastin worldwide also markets lucentis us lucentis approved worldwide treatment wet macular degeneration retinal disorders avastin used treat certain cancers price lucentis much higher avastin many ophthalmologists began compounding pharmacies formulate avastin administration eye began treating patients four trusts national health service uk issued policies approving use payment administering avastin macular degeneration order save money even though avastin approved april failing persuade trusts uncertain whether avastin safe effective lucentis order retain market lucentis novartis announced would sue however july novartis offered significant discounts kept confidential trusts trusts agreed change november novartis dropped summer two japanese universities retracted several publications clinical trials purported show valsartan branded diovan cardiovascular benefits found statistical analysis manipulated novartis employee participated statistical analysis disclosed relationship novartis affiliation osaka city university result several japanese hospitals stopped using drug media outlets ran reports scandal january japans health ministry filed criminal complaint tokyo public prosecutors office novartis unspecified number employees allegedly misleading consumers advertisements used research support benefits july prosecutors office announced formally charging company one january novartis began investigated us greek authorities allegedly bribing greek public officials period scheme included two former prime ministers several former health ministers many high ranking party members nea dimokratia pasok ruling parties well manager novartis greek branch prohibited leaving ministers deputy described allegations biggest scandal since creation greek state caused annual state expenditure medicine ministers involved scandal denied allegations sought paint case political targeting fabrication syriza opposition however greek judicial council ruled scandal besides bribery involves artificial increases price several medicines case also involves money laundering suspicions illegal funds four billion euros billion june novartis reached settlements us department justice doj us securities exchange commission sec resolving foreign corrupt practices act fcpa investigations historical conduct company subsidiaries part resolutions novartis current former subsidiaries would pay million doj million novartis paid million essential consultants entity owned michael cohen following inauguration donald trump cohen paid monthly payment novartis claims paid cohen help understand influence new administrations approach drug pricing july us senate committee report white house access sale revealed novartis ags relationship cohen longer detailed novartis initially stated relationship ceased month entering million contract cohens consulting firm since consultants able provide information pharmaceutical company needed later became clear however thenceo joseph jimenez cohen communicated via email multiple times included ideas lower drug prices discussed president according report several ideas appeared later trumps drug pricing plan released early pharmaceutical companies protected reduced already received approval zolgensma may june avexis novartis company voluntarily disclosed fda data previously submitted agency part biologics license application bla package inaccurate specifically data manipulation related vivo murine potency assay used early development product issue fda wider community taken avexis aware data manipulation early march almost two months bla approved compound problem early august emerged senior manager sold almost million worth stock immediately fda probe became public august company informed fda problem september fda still preparing response scandalcitation needed novartis committed decades eliminate leprosy providing free multidrug therapy endemic countries since httpsenwikipediaorgwikinovartis